Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review
Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East and North Africa (MENA) and Europe and rest of the world. Hikma Pharmaceuticals is headquartered in London, the UK.
Hikma Pharmaceuticals Plc Key Recent Developments
Feb 25,2021: Hikma delivers strong performance in 2020
Feb 18,2021: Hikma donates over $4 million USD in medicines and signs new long-term partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the National Children's Cancer Society
Nov 30,2020: Amarin files patent infringement lawsuit against Hikma
Nov 05,2020: Hikma Pharmaceuticals - Board and committee changes
Nov 05,2020: Hikma continues strong 2020 performance and updates full year guidance
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East and North Africa (MENA) and Europe and rest of the world. Hikma Pharmaceuticals is headquartered in London, the UK.
Hikma Pharmaceuticals Plc Key Recent Developments
Feb 25,2021: Hikma delivers strong performance in 2020
Feb 18,2021: Hikma donates over $4 million USD in medicines and signs new long-term partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the National Children's Cancer Society
Nov 30,2020: Amarin files patent infringement lawsuit against Hikma
Nov 05,2020: Hikma Pharmaceuticals - Board and committee changes
Nov 05,2020: Hikma continues strong 2020 performance and updates full year guidance
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Hikma Pharmaceuticals Plc - Key Facts
Hikma Pharmaceuticals Plc - Key Employees
Hikma Pharmaceuticals Plc - Key Employee Biographies
Hikma Pharmaceuticals Plc - Major Products and Services
Hikma Pharmaceuticals Plc - History
Hikma Pharmaceuticals Plc - Company Statement
Hikma Pharmaceuticals Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
SECTION 2 – COMPANY ANALYSIS
Company Overview
Hikma Pharmaceuticals Plc - Business Description
Business Segment: Branded
Overview
Performance
Business Segment: Generics
Overview
Performance
Business Segment: Injectables
Overview
Performance
Business Segment: Others
Performance
Geographical Segment: Europe and Rest of the World
Performance
Geographical Segment: MENA
Performance
Geographical Segment: United Kingdom
Performance
Geographical Segment: United States
Performance
Hikma Pharmaceuticals Plc - Corporate Strategy
Hikma Pharmaceuticals Plc - SWOT Analysis
SWOT Analysis - Overview
Hikma Pharmaceuticals Plc - Strengths
Hikma Pharmaceuticals Plc - Weaknesses
Hikma Pharmaceuticals Plc - Opportunities
Hikma Pharmaceuticals Plc - Threats
Hikma Pharmaceuticals Plc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Feb 25, 2021: Hikma delivers strong performance in 2020
Feb 18, 2021: Hikma donates over $4 million USD in medicines and signs new long-term partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the National Children's Cancer Society
Nov 30, 2020: Amarin files patent infringement lawsuit against Hikma
Nov 05, 2020: Hikma Pharmaceuticals - Board and committee changes
Nov 05, 2020: Hikma continues strong 2020 performance and updates full year guidance
Oct 20, 2020: Hikma and Arecor expand collaboration
Aug 18, 2020: DoseID launches to expand RFID interoperability and performance in healthcare
Aug 07, 2020: Hikma Pharmaceuticals : Half-year Report
Aug 07, 2020: Hikma delivers strong first half performance and raises full year guidance
Jun 25, 2020: Jochen Gann resigns from the Board of Hikma
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Hikma Pharmaceuticals Plc - Key Facts
Hikma Pharmaceuticals Plc - Key Employees
Hikma Pharmaceuticals Plc - Key Employee Biographies
Hikma Pharmaceuticals Plc - Major Products and Services
Hikma Pharmaceuticals Plc - History
Hikma Pharmaceuticals Plc - Company Statement
Hikma Pharmaceuticals Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
SECTION 2 – COMPANY ANALYSIS
Company Overview
Hikma Pharmaceuticals Plc - Business Description
Business Segment: Branded
Overview
Performance
Business Segment: Generics
Overview
Performance
Business Segment: Injectables
Overview
Performance
Business Segment: Others
Performance
Geographical Segment: Europe and Rest of the World
Performance
Geographical Segment: MENA
Performance
Geographical Segment: United Kingdom
Performance
Geographical Segment: United States
Performance
Hikma Pharmaceuticals Plc - Corporate Strategy
Hikma Pharmaceuticals Plc - SWOT Analysis
SWOT Analysis - Overview
Hikma Pharmaceuticals Plc - Strengths
Hikma Pharmaceuticals Plc - Weaknesses
Hikma Pharmaceuticals Plc - Opportunities
Hikma Pharmaceuticals Plc - Threats
Hikma Pharmaceuticals Plc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Feb 25, 2021: Hikma delivers strong performance in 2020
Feb 18, 2021: Hikma donates over $4 million USD in medicines and signs new long-term partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the National Children's Cancer Society
Nov 30, 2020: Amarin files patent infringement lawsuit against Hikma
Nov 05, 2020: Hikma Pharmaceuticals - Board and committee changes
Nov 05, 2020: Hikma continues strong 2020 performance and updates full year guidance
Oct 20, 2020: Hikma and Arecor expand collaboration
Aug 18, 2020: DoseID launches to expand RFID interoperability and performance in healthcare
Aug 07, 2020: Hikma Pharmaceuticals : Half-year Report
Aug 07, 2020: Hikma delivers strong first half performance and raises full year guidance
Jun 25, 2020: Jochen Gann resigns from the Board of Hikma
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Hikma Pharmaceuticals Plc, Key Facts
Hikma Pharmaceuticals Plc, Key Employees
Hikma Pharmaceuticals Plc, Key Employee Biographies
Hikma Pharmaceuticals Plc, Major Products and Services
Hikma Pharmaceuticals Plc, History
Hikma Pharmaceuticals Plc, Subsidiaries
Hikma Pharmaceuticals Plc, Joint Venture
Hikma Pharmaceuticals Plc, Key Competitors
Hikma Pharmaceuticals Plc, Ratios based on current share price
Hikma Pharmaceuticals Plc, Annual Ratios
Hikma Pharmaceuticals Plc, Annual Ratios (Cont...1)
Hikma Pharmaceuticals Plc, Annual Ratios (Cont...2)
Hikma Pharmaceuticals Plc, Interim Ratios
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Hikma Pharmaceuticals Plc, Key Facts
Hikma Pharmaceuticals Plc, Key Employees
Hikma Pharmaceuticals Plc, Key Employee Biographies
Hikma Pharmaceuticals Plc, Major Products and Services
Hikma Pharmaceuticals Plc, History
Hikma Pharmaceuticals Plc, Subsidiaries
Hikma Pharmaceuticals Plc, Joint Venture
Hikma Pharmaceuticals Plc, Key Competitors
Hikma Pharmaceuticals Plc, Ratios based on current share price
Hikma Pharmaceuticals Plc, Annual Ratios
Hikma Pharmaceuticals Plc, Annual Ratios (Cont...1)
Hikma Pharmaceuticals Plc, Annual Ratios (Cont...2)
Hikma Pharmaceuticals Plc, Interim Ratios
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Hikma Pharmaceuticals Plc, Performance Chart (2016 - 2020)
Hikma Pharmaceuticals Plc, Ratio Charts
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Performance Chart (2016 - 2020)
Hikma Pharmaceuticals Plc, Ratio Charts
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021